Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) EBITDA (2020 - 2025)

Historic EBITDA for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $14.1 million.

  • Tango Therapeutics' EBITDA rose 14280.07% to $14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$110.3 million, marking a year-over-year increase of 1557.05%. This contributed to the annual value of -$130.2 million for FY2024, which is 3300.77% down from last year.
  • Per Tango Therapeutics' latest filing, its EBITDA stood at $14.1 million for Q3 2025, which was up 14280.07% from -$41.0 million recorded in Q2 2025.
  • Tango Therapeutics' 5-year EBITDA high stood at $14.1 million for Q3 2025, and its period low was -$42.5 million during Q1 2025.
  • Its 5-year average for EBITDA is -$25.2 million, with a median of -$27.9 million in 2022.
  • As far as peak fluctuations go, Tango Therapeutics' EBITDA tumbled by 95816271.19% in 2021, and later soared by 14280.07% in 2025.
  • Quarter analysis of 5 years shows Tango Therapeutics' EBITDA stood at -$22.8 million in 2021, then fell by 22.4% to -$27.9 million in 2022, then dropped by 7.12% to -$29.9 million in 2023, then plummeted by 36.84% to -$40.9 million in 2024, then surged by 134.4% to $14.1 million in 2025.
  • Its last three reported values are $14.1 million in Q3 2025, -$41.0 million for Q2 2025, and -$42.5 million during Q1 2025.